Geode Capital Management LLC Upped Holding in Abbvie INC (ABBV)

February 15, 2018 - By Ivan Hodges

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It turned negative, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. America First Invest Advsr Ltd accumulated 1,673 shares. Lowe Brockenbrough Inc holds 0.63% or 46,027 shares in its portfolio. Guggenheim Cap Limited holds 0.34% or 1.64 million shares. Sns Financial Grp Inc Limited Liability Company reported 1.48% in AbbVie Inc. (NYSE:ABBV). Bp Pcl has 187,354 shares for 0.59% of their portfolio. Counselors Incorporated holds 1.1% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 253,354 shares. Commonwealth Equity Ser holds 634,688 shares or 0.34% of its portfolio. Private Wealth Advsr has 0.38% invested in AbbVie Inc. (NYSE:ABBV) for 10,463 shares. Hite Hedge Asset Mngmt Llc reported 2,560 shares. Capital Invest Of America Inc holds 3,536 shares. Optimum Investment holds 1.33% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 44,565 shares. Concorde Asset Mngmt has invested 0.21% in AbbVie Inc. (NYSE:ABBV). Autus Asset Mngmt Ltd reported 0.26% stake. Cambridge Tru invested in 0.38% or 64,319 shares. Laurion Cap Mngmt Lp holds 0.01% or 17,996 shares.

Since September 11, 2017, it had 0 insider buys, and 5 sales for $25.59 million activity. The insider RICHMOND TIMOTHY J. sold 87,040 shares worth $8.57 million. $589,512 worth of stock was sold by Michael Robert A. on Thursday, September 28. 145,510 shares were sold by Schumacher Laura J, worth $14.07 million. On Monday, September 11 SALEKI-GERHARDT AZITA sold $705,655 worth of AbbVie Inc. (NYSE:ABBV) or 8,300 shares.

Geode Capital Management Llc increased its stake in Abbvie Inc (ABBV) by 2.14% based on its latest 2017Q3 regulatory filing with the SEC. Geode Capital Management Llc bought 321,142 shares as the company’s stock rose 6.17% with the market. The institutional investor held 15.35M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $1.36B, up from 15.02M at the end of the previous reported quarter. Geode Capital Management Llc who had been investing in Abbvie Inc for a number of months, seems to be bullish on the $182.52 billion market cap company. The stock increased 1.11% or $1.25 during the last trading session, reaching $114.33. About 5.65 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 15, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Geode Capital Management Llc, which manages about $270.92B US Long portfolio, decreased its stake in Discovery Communications (NASDAQ:DISCK) by 291,505 shares to 2.32 million shares, valued at $46.97M in 2017Q3, according to the filing. It also reduced its holding in Imperial Oil Ltd (NYSEMKT:IMO) by 110,688 shares in the quarter, leaving it with 46,907 shares, and cut its stake in Xerox Corp.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: which released: “AbbVie: Looking Very Attractive In 2018” on February 07, 2018, also with their article: “AbbVie Is Ruining Pharma Earnings Season” published on January 31, 2018, published: “Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?” on February 12, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: and their article: “AbbVie to buy back $10 billion of shares, raises dividend” published on February 15, 2018 as well as‘s news article titled: “AbbVie Looks Positioned For Outperformance” with publication date: January 31, 2018.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained the shares of ABBV in report on Thursday, May 25 with “Buy” rating. BMO Capital Markets maintained it with “Market Perform” rating and $84 target in Thursday, November 16 report. The rating was initiated by William Blair with “Outperform” on Friday, February 5. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Thursday, September 28 by Piper Jaffray. Jefferies maintained AbbVie Inc. (NYSE:ABBV) on Thursday, January 4 with “Buy” rating. The firm earned “Neutral” rating on Monday, September 25 by UBS. The firm has “Underperform” rating by BMO Capital Markets given on Tuesday, January 30. The firm has “Outperform” rating by Leerink Swann given on Monday, October 2. The firm has “Buy” rating by SunTrust given on Wednesday, July 22. Jefferies maintained it with “Buy” rating and $10 target in Friday, September 15 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.